Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin ?-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)-Reference-Cited by-同舟云学术

Pharmacokinetic contribution to the improved therapeutic selectivity of a novel bromoethylamino prodrug (RB 6145) of the mixed-function hypoxic cell sensitizer/cytotoxin ?-(1-aziridinomethyl)-2-nitro-1H-imidazole-1-ethanol (RSU 1069)

Published:1991 Issue:1 Volume:29 Page:37-47
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother. Pharmacol.

Author:

Binger Michael,Workman Paul

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/BF00686334.pdf

Reference23 articles.

1. Adams GE, Ahmed I, Sheldon PW, Stratford IJ (1984) Radiation sensitization and chemopotentiation: RSU 1069, a compound more efficient than misonidazole in vitro and in vivo. Br J Cancer 49: 571

2. Brown JM, Workman P (1980) Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole. Radiat Res 82: 171

3. Brown JM, Yu NY, Brown DM, Lee WW (1981) A 2-nitro-imidazole amide which should be superior to misonidazole as a radiosensitizer for clinical use. Int J Radiat Oncol Biol Phys 7: 695

4. Cole S, Stratford IJ, Adams GE, Fielden EM, Jenkins TC (1991) Dualfunction 2-nitroimidazoles as hypoxic cell radiosensitizers and bioreductive cytotoxins: in vivo evaluation in KHT murine sarcomas. Radiat Res (in press)

5. Cole S, Stratford IJ, Nolan J, Bowler J, Edwards H, Wright EG, Lorimore SA, Adams GE (1991) Oral dosing with RSU 1069 or RB 6145 maintains their potency as hypoxic cell radiosensitizers and cytotoxins but reduces systemic toxicity compared with parenteral administration in mice. Int J Radiat Oncol Biol Phys (in press)

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Design of anticancer prodrugs for reductive activation;Medicinal Research Reviews;2009-01

2. CL-20 photodecomposition: Ab initio foundations for identification of products;Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy;2008-11

3. Combining bioreductive drugs and radiation for the treatment of solid tumors;Seminars in Radiation Oncology;2003-01

4. Development of a chiral HPLC method to evaluate in vivo enantiomeric inversion of an unstable, polar radiosensitizer in plasma;Journal of Pharmaceutical and Biomedical Analysis;1999-11

5. Prodrugs in Cancer Chemotherapy;Enzyme-Prodrug Strategies for Cancer Therapy;1999